Aurora Cannabis : IR presentation FY25 Q2 Final
ACB.TO
I NV ES TOR
P RE S E NT A TI O N
FY25 Q2
November 2024
Disclaimer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward- looking statements in this presentation include, but are not limited to, statements with respect to: the Company's strategy, plans, and path to achieving positive free cash flow; the Company's net cash position and ability to pursue profitable growth, including through M&A; the acquisition of MedReleaf Australia and associated benefits, including, but not limited to, the positioning of the Company as the largest global medical cannabis company in nationally legal markets, expected improvements in revenue contributions and gross margins; expectations for the size of the Australian market; the Bevo business, including, but not limited to, the acceleration of Bevo's business plan and expectations for that business to continue to drive revenue and EBITDA growth; the Company's Canadian and European medical market Leadership; other growth opportunities in the domestic and international medical and recreational cannabis segments, including in Germany; the Company's science and innovation program and the associated benefits, including improvements in cultivation yields, product consistency, and crop quality and further launches of new cultivars in international markets; competitive advantages in science, medical, product innovation and regulatory expertise; enhancements to the Company's medical eCommerce site and associated benefits; and the creation of shareholder value. Forward-looking statements are based on certain opinions, estimates and assumptions of Aurora's management in light of management's experience and perception of historical trends, current conditions and expected developments at the time the statements are made,
including expected growth, results of operations, performance, industry trends and conditions, opinions, estimates and assumptions to be reasonable, based on information currently available,
the current and future regulatory environment and growth opportunities. While Aurora considers these they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking
statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic .S.; realization of funded production estimates; changes in tax treatment; the ability of Aurora to implement its business strategies; competition; product demand; changes in prices of required commodities; currency and interest rate fluctuations; the effects of and responses to the COVID-19 pandemic; that the adult consumer market for cannabis in Canada and CBD in the U.S. and the global medical cannabis market, will prove smaller than estimated; whether the Company will be able to identify consumer trends and stock desirable products, identify partnering opportunities, right-size production facilities, and maintain SG&A costs; and other risks and uncertainties set out under the heading "Risk Factors" in Aurora's annual information form dated June 20, 2024 and filed with Canadian securities regulators available on Aurora's issuer profile on SEDAR at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov.
Recipients are cautioned that the foregoing risks are not exhaustive and other factors could also adversely affect Aurora and its business and operations. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
No securities of Aurora any kind are being offered as part of this presentation. Before making an investment of any kind in securities of Aurora, potential investors are urged to read Aurora's public disclosure materials filed under Aurora's issuer profile on SEDAR at www.sedarplus.comand filed with and available on the SEC's website at www.sec.gov.
Diversified Global Business Model Focus on Defensive, Stable, High Margin Segments
International
Medical
International medical revenue increased 93% in Q2 FY 2025 compared to the prior year period.
Leadership in key markets such as Germany, Poland, the UK, and Australia
Canadian Medical
#1 Canadian Medical share by revenue.
Consistent margins, direct- to-patient model.
Plant Propagation
Controlling interest in Bevo, one of the largest suppliers of propagated vegetables and ornamental plants in North America.
Track record of profitable, cash flow positive operations with plans for future growth.
Adult Recreational
Ability to deliver products that provide exceptional customer value in all price tiers, while at the same time achieving strong contribution and gross margins
Science & Innovation
Delivering a continuous stream of new and exciting products with desirable high THC and terpene levels.
Innovations in genetics result in all-in per unit costs that are at least 30% better than legacy cultivars.
Leading Global Cannabis Platform
Leadership in Key Global Cannabis Markets
CANADA: 39m population
UNITED KINGDOM: 68m population
high-growth market due to less rigid prescriber regulations
education and training to registered healthcare professionals with 300+ registrations to date
FRANCE: 65m population
pilot program as sole supplier
• Actively engaged in consultations around medical market framework, expected to launch in 2026 pending further regulatory reviews
GERMANY: 83m population
• First pillar of cannabis decriminalization took effect April 1, changing the cannabis paradigm in the country and easing access for patients
POLAND: 40m population
• Aurora consistently maintains top 3 market share by volume
AUSTRALIA: 27m population
• Potential to be the largest medical market in the
world outside of North America
• Significant sales and patient growth driven by
uptick in authorized prescribers
SWITZERLAND:
• Acquired MedReleaf Australia in Feb. 2024:
9m population
the second largest medical cannabis distributor
• Widened distribution
in the country
• Aurora one of the first Canadian LPs to receive
channels and the
introduction of new
GMP certification from the Australian regulatory
cultivars
agency
resin cartridge products, alongside an expanded range of next generation cultivars
NEW ZEALAND: 5m population
• Completed first shipment of medical cannabis in May 2024, with further
innovation planned
5
6
Australia & New Zealand Market Leadership
Following the acquisition of MedReleaf Australia, the # 2 player in the market, Aurora has expanded its medical product portfolio, to meet the growing needs of the patients in Australia and New Zealand
Consistent Revenue Stream and Margin Leader
• #2 Market Share >20% by revenue and by pharmacy dispensed volumes1
Premium
• Strong growth across all product categories: Flower, Oils, Pastilles, Vapes.
High-quality cannabis products for
• New Zealand showed strong growth following the initial launch in Q1.
experienced cannabis patients
Core
Pharmaceutical-grade cannabis products
and innovative formals for patients
seeking consistent quality
Value
Affordable pricing for
Concession Card Holders
Key Differentiator: Consistent
quality and availability
Market leading Product Portfolio
Strong Reputation of Consistency, Quality, and Availability
1. Nostradata, 2:These terms are Non-GAAP Measures and are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the FY25 Q2 MD&A, filed November 6, 2024. Refer to the "Adjusted Gross Margin" & "Adjusted EBITDA" section for a reconciliation to IFRS equivalent.
7
Latest Product Launches Australia & New Zealand
This year, Aurora launched a full portfolio of products and formats across market segments. In Q2, Aurora rounded out its portfolio by launching nine new edible SKUs under the Aurora and IndiMed brands and re-introducing Pink Kush to the market under IndiMed Tempo 19 Indica.
FY25 Q1
FY25 Q2
Dried Flower
Vapes & Concentrates
Pastilles
•
CraftPlant Pink Diesel
• Aurora 1.2g Sourdough Vape
• Aurora 5 Pack Pastilles
•
CraftPlant Cosmic Cream
• Aurora 1.2g Electric Honeydew Vape
• IndiMed 30 Pack Pastilles
•
Aurora Black Jelly
• IndiMed 1.2g
Sativa Vape
• IndiMed 5 Pack Pastilles
•
Aurora Chemango Kush
• IndiMed 1.2g
Indica Vape
Dried Flower
•
Aurora Moon Berry
•
Aurora Luminarium (NZ)
• IndiMed Tempo 19 Indica (Pink Kush)
•
Aurora Sedaprem (NZ)
•
Aurora Equiposa (NZ)
8
Canadian Medical Leadership
Aurora is leading the market with four owned brands and a wide variety of marketplace offerings. Aurora partnered with Vectura Fertin Pharma to launch LUOTM, an innovative CBD lozenge
Consistent Revenue Stream and Margin Leader
Value
Core
"Your Ally in Medical Cannabis"
"Better Days Ahead"
Straightforward and dependable
Science-backed innovation
Premium
Super Premium
"The Medical Grade Standard"
"A Natural Part of Your Recovery"
Consistent high-quality product for an
Highest quality cannabis
advanced consumption experience
Best in Class Patient Experience
Breadth and depth of product portfolio
1. These terms are Non-GAAP Measures and are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the FY25 Q2 MD&A, filed November 6, 2024. Refer to the "Adjusted Gross Margin" & "Adjusted EBITDA" section for a reconciliation to IFRS equivalent.
9
Latest Canadian Medical Innovations
Dried Flower
Lotions & Topicals
Oils & Capsules
Edibles & Beverages
Vapes & Concentrates
•
Medreleaf Noculus
• Turmeric and Arnica
• Morning, Noon & Night
• Luo TM Vanilla mint lozenges
•
Tastys Blue Raspberry
•
WMMC Kootna Kush
relief balm
CBD Oral Spray
Vape
•
WMMC Pomelo Fresco
• Honeydew Infused Pre roll
•
Mango Infused Pre roll
10
Disclaimer
Aurora Cannabis Inc. published this content on November 06, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 06, 2024 at 16:28:01.696.